Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022.
The schedule for the press release and conference call/webcast is as follows:
| • MAESTRO-NASH Press Release: | December 19th, 2022 at 7:00 am EST | |
| • MAESTRO-NAFLD-1 Conference Call: | December 19th, 2022 at 8:00 am EST | |
To access the live webcast of the call with slides please visit the Investors section of Madrigal's website or click here. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. An archived webcast will be available on the Madrigal website after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. MDGL is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.
Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
